What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|Sep. 21||Weekly Gain||My Watchlist|
IRIS soared last week after receiving a buyout offer. Shareholders of the medical diagnostics provider will be cashed out at $19.50 a share in a tender offer.
Acadia Pharmaceuticals had a strong midweek run. Top-line results for the critical phase 3 study of a promising drug to treat Parkinson's-related psychosis are expected by the end of November. Expect plenty of volatile trading in the coming weeks as the company reaches that important revelation.
NII Holdings made a winning connection after CEO Steve Dussek increased his stake in the company, by 12%. It's a strong show of confidence for the Latin American wireless service provider.
Complete Genomics notched most of last week's gains on Monday, after the gene-sequencing specialist revealed that it would be acquired by China's BGI-Shenzhen. Complete Genomics had put itself up for sale when it initiated a strategic review earlier this year.
Nanosphere gained ground after the TheStreet.com published a bullish article on the provider of advanced molecular diagnostics systems. The shares also got a continued boost on Friday morning after announcing that its CFO would be speaking at an investor conference.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
More from The Motley Fool
3 Keys for Acadia Pharmaceuticals to Succeed in 2018
Acadia CEO Stephen Davis outlines the path to success for the biotech at the J.P. Morgan Healthcare Conference.
Here's How Acadia Pharmaceuticals Crushed It in 2017
Nuplazid's sales are soaring, but Acadia's stock price hasn't responded in kind. Is that mismatch creating a buying opportunity for investors?
3 Stocks That Turned $8,000 Into at Least $138,000 in 5 Years
Some stocks have outperformed the market, and then there's MGP Ingredients, Acadia Pharma, and Netflix.